PCI Biotech Holding Logo

PCI Biotech Holding

PCIB | OL

Overview

Corporate Details

ISIN(s):
NO0010405640
LEI:
5967007LIEEXZXFIGG77
Country:
Norway
Address:
Ullernchausséen 64, 0379 OSLO
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

PCI Biotech Holding is a biopharmaceutical company developing therapeutic products based on its proprietary Photochemical Internalisation (PCI) technology. This platform is designed to enable the efficient intracellular delivery of therapeutic molecules. The company's development programs are focused on several areas, including immunotherapy and dermatology, with the photosensitiser fimaporfin (Amphinex) as a key product candidate for cancer treatment. Additionally, PCI Biotech applies its technology to bioprocessing, aiming to advance and improve the manufacturing of viral vectors for gene therapies. The technology originated from research at the Oslo Radium Hospital.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for PCI Biotech Holding. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-26 16:14
Report Publication Announcement
PCI Biotech: Invitation to first half 2025 results presentation and corporate u…
English 2.3 KB
2025-08-22 14:15
Major Shareholding Notification
Flaggemelding
Norwegian 411 bytes
2025-08-22 11:09
Major Shareholding Notification
Flaggemelding
Norwegian 451 bytes
2025-08-18 20:39
Regulatory News Service
PCI Biotech announces discontinuation of development of the PCL technology and …
English 3.4 KB
2025-05-22 09:45
Post-Annual General Meeting Information
PCI Biotech: Minutes of Annual General Meeting 2025
Norwegian 449.8 KB
2025-05-22 09:45
Post-Annual General Meeting Information
PCI Biotech: Minutes of Annual General Meeting 2025
English 866 bytes
2025-05-20 20:08
Declaration of Voting Results & Voting Rights Announcements
PCI BIotech: Disclosure of voting rights for Chair of the Board
English 1.2 KB
2025-04-30 08:00
Pre-Annual General Meeting Information
Notice of Annual General Meeting 2025
Norwegian 188.6 KB
2025-04-30 08:00
Pre-Annual General Meeting Information
Notice of Annual General Meeting 2025
Norwegian 146.9 KB
2025-04-30 08:00
Pre-Annual General Meeting Information
Notice of Annual General Meeting 2025
English 167.8 KB
2025-04-30 08:00
Pre-Annual General Meeting Information
Notice of Annual General Meeting 2025
English 208.0 KB
2025-04-30 08:00
Pre-Annual General Meeting Information
Notice of Annual General Meeting 2025
English 977 bytes
2025-04-24 15:30
Annual Report (ESEF)
PCI Biotech Holding ASA: Annual Report 2024
English 5.4 MB
2025-04-24 15:30
Annual Report
PCI Biotech Holding ASA: Annual Report 2024
English 1.2 MB
2025-04-24 15:30
Report Publication Announcement
PCI Biotech Holding ASA: Annual Report 2024
English 908 bytes

Automate Your Workflow. Get a real-time feed of all PCI Biotech Holding filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for PCI Biotech Holding via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
1NKEMIA Logo
Offers contract R&D, develops tech platforms, and invests in life sciences ventures.
Spain IKM
2cureX AB Logo
Tests cancer drugs on patient-derived micro-tumors for personalized oncology treatments.
Sweden 2CUREX
4SC AG Logo
Developing epigenetic small-molecule drugs for cancers with high unmet medical needs.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using an OMV platform for major infectious diseases.
Sweden ABERA
ABIVAX Logo
Developing oral drugs for chronic inflammatory diseases like ulcerative colitis and Crohn's disease.
France ABVX
Abliva Logo
A clinical-stage biotech developing medicines for rare primary mitochondrial diseases.
Sweden ABLI
Achiko AG Logo
A liquidated health tech firm that developed aptamer diagnostics and a COVID-19 passport app.
Switzerland ACHI
Acticor Biotech Logo
Biopharma developing first-in-class drugs for acute stroke and other thrombotic diseases.
France ALACT
Active Biotech Logo
Develops immunotherapies for cancer and inflammatory diseases with significant unmet needs.
Sweden ACTI
Addex Therapeutics Ltd Logo
Develops oral small molecule drugs, allosteric modulators, for neurological disorders.
Switzerland ADXN